Brought to you by 
UCB and Celltech to develop and market CDP870 for arthritis
13 Jul 2004
Executive Summary
Celltech Group PLC has licensed UCB SA development and marketing rights to CDP870, its anti-TNF-alpha PEGylated antibody fragment. The license is exclusive for rheumatoid arthritis and other indications, excluding Crohn's disease. Celltech has retained exclusive development and commercialization rights for Crohn's in North America, major European markets, Australia, and New Zealand, with UCB getting development and commercialization rights in other territories.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
UCB and Celltech to develop and market CDP870 for arthritis
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice